Bristol Myers Squibb Company (NYSE:BMY) Given Consensus Recommendation of “Hold” by Analysts

Bristol Myers Squibb Company (NYSE:BMY) has been given a consensus rating of “Hold” by the twenty-one analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $54.6154.

Several equities research analysts have issued reports on the stock. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Morgan Stanley reissued an “underweight” rating and issued a $37.00 price target (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Truist Financial set a $65.00 price objective on Bristol Myers Squibb in a research note on Wednesday, December 3rd.

Bristol Myers Squibb Trading Down 0.7%

Bristol Myers Squibb stock opened at $54.26 on Wednesday. The business has a 50 day moving average price of $48.16 and a two-hundred day moving average price of $47.22. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $63.33. The stock has a market cap of $110.45 billion, a price-to-earnings ratio of 18.33, a price-to-earnings-growth ratio of 8.37 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.Bristol Myers Squibb’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, equities analysts forecast that Bristol Myers Squibb will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.6%. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is presently 83.78%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Trifecta Capital Advisors LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth about $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb in the second quarter valued at about $25,000. CBIZ Investment Advisory Services LLC grew its stake in Bristol Myers Squibb by 66.0% during the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 231 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of Bristol Myers Squibb during the first quarter worth approximately $36,000. Finally, Harbor Capital Advisors Inc. raised its stake in shares of Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Several bullish write-ups argue BMY remains undervalued despite the year‑end rebound, highlighting strong cash generation, buyback/dividend support and an attractive valuation relative to peers. Bristol-Myers Squibb Surges Into Year-End
• Positive Sentiment: Analysis highlights BMY’s ability to print cash and sustain returns despite patent pressures — a bullish case for long-term value investors. Pharma Giant Still Undervalued And Printing Cash
• Positive Sentiment: Income-focused pieces highlight a ~4.6% dividend yield and argue the yield plus buybacks make BMY attractive for yield/total‑return investors. Still Undervalued And Generating 4.65% Dividend Yield
• Positive Sentiment: General valuation pieces ask whether BMY is still undervalued after the rebound, reinforcing buy‑and‑hold narratives used by pro‑value investors. Is Bristol Myers Squibb (BMY) Still Undervalued
• Positive Sentiment: BMY appears on lists of “top value stocks” for 2026, which can attract retail/income flows into the name. 3 Top Value Stocks to Buy and Hold for 2026
• Neutral Sentiment: BMO (via TipRanks coverage) maintained a Hold rating, citing stable cash flows but a slower-than-expected Cobenfy ramp — a steadying but non‑bullish analyst view. Stable Cash Flows Offset by Slower Cobenfy Ramp
• Neutral Sentiment: Industry coverage notes multiple drugmakers struck pricing deals with the administration; sector sentiment is generally positive on regulatory clarity but implications for individual company sales vary. Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
• Neutral Sentiment: Analysts are parsing the government pricing deal’s net effect on sales — some loss in Eliquis revenue for covered populations is possible, but the deal also reduces regulatory uncertainty. Will the Recent Pricing Deal With the Government Impact BMY’s Sales?
• Negative Sentiment: BMY agreed to supply Eliquis free to Medicaid recipients starting in 2026 and to donate seven tons of the active ingredient — a move that could reduce Eliquis revenues in the Medicaid channel and pressure overall U.S. sales, which is the primary near‑term negative driver. Bristol-Myers Offers Eliquis Free to Medicaid Patients

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.